bluebird bio To Present Interim Data On Phase 2 Starbeam Study To Evaluate Lenti-D

bluebird bio Inc

revealed that interim data from its ongoing stage two Starbeam Study (ALD-102) to evaluate the Lenti-D product candidate in pediatric patients with cerebral adrenoleukodystrophy would be presented at the American Academy of Neurology's annual meeting. According to the company, the data would be highlighted in an oral presentation by Florian Eichler, who is a Director of the Leukodystrophy Service at Massachusetts General Hospital for Children. Boston Children's Cancer and Blood Disorders Center President, David Williams, commented, "CALD is a rare and deadly disease, and currently the only available treatment option is allogeneic hematopoietic stem cell transplant, which is often challenging for patients without a matched sibling donor. t is exciting to see a potential autologous treatment option for these patients. While these study results are early, they are encouraging, and we look forward to further understanding the impact that treatment with Lenti-D gene therapy could have on patients as these data evolve." bluebird said that the study was a global and multi-center study to assess the safety and efficacy of an investigational gene therapy in boys aged maximum of 17 years. The company indicated that 17 patients were provided with Lenti-D product and that all patients had a minimum of six months follow up while eight patients had between 12 and 24 months of follow up. The stock traded down by 1.4% on Wednesday.